Markets:

Overview

News

Currencies

International

Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

73.50 +1.06 (+1.46%)

Streaming Delayed Price Updated: 12:03 PM EDT, Sep 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 17, 2023

Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...

Via Benzinga

BridgeBio (NASDAQ: BBIO) Announces Exceptionally Positive Outcomes in Phase 3 Study of Acoramidis

July 17, 2023

BridgeBio Pharma (NASDAQ: BBIO), a leading biopharmaceutical company, announced significant outcomes from the ATTRibute-CM, their Phase 3 study of acoramidis,

Via Spotlight Growth

Nasdaq Gains 100 Points; Guaranty Bancshares Posts Upbeat Results ↗

July 17, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Monday. The Dow traded up 0.19% to 34,574.01 while the NASDAQ rose 0.71% to 14,214.50. The S&P...

Via Benzinga

Why BridgeBio Pharma Stock Is Plunging Today ↗

June 15, 2023

A cautionary note from JPMorgan is weighing on the biotech's shares today.

Via The Motley Fool

Why Are Telecom Stocks Down Today? ↗

July 17, 2023

Telecom stocks aren't doing so how on Monday after several players in the space were hit by downgrades and lowered price targets from Citi.

Via InvestorPlace

BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease ↗

July 17, 2023

The companies are working on treatments for a leading cause of heart failure.

Via Investor's Business Daily

BridgeBio Pharma Inc. (NASDAQ: BBIO) Records 52-Week High Monday Morning

July 17, 2023

Via Investor Brand Network

Why Is BridgeBio (BBIO) Stock Up 63% Today? ↗

July 17, 2023

BridgeBio Pharma (BBIO) stock is climbing higher on Monday as investors react to results from a recent Phase 3 clinical trial.

Via InvestorPlace

US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July ↗

July 17, 2023

U.S. stocks traded slightly higher this morning, with the Dow Jones moving higher by around 20 points on Monday. Following the market opening Monday, the Dow traded up 0.06% to 34,529.57 while the...

Via Benzinga

You Can't Afford to Miss Monday's 2 Nasdaq Biotech Stock Movers ↗

July 17, 2023

Big gains are afoot even as the markets prepare for a flat open.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 17, 2023

Via Benzinga

Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket ↗

July 17, 2023

Gainers

Via Benzinga

BridgeBio Pharma Shares Are Shooting Higher Today - Here's Why ↗

July 17, 2023

BridgeBio Pharma Inc (NASDAQ: BBIO) released results from ATTRibute-CM Phase 3 study of acoramidis in transthyretin

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

July 17, 2023

It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!

Via InvestorPlace

Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 17, 2023

U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

July 17, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

2 Nasdaq Stocks That Could Soar This Week ↗

July 16, 2023

BridgeBio Pharma and Roivant Sciences could make big moves this week.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 14, 2023

Via Benzinga

BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023

July 14, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma

July 12, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 12, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 11, 2023

Via Benzinga

BioMarin Presents ~20% Upside Amid Voxzogo's Success and Slow Roctavian Uptake, Analyst Says ↗

July 05, 2023

BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (NASDAQ: BMRN) to Outperform from Market Perform, and the price target remains at $102,

Via Benzinga

2 Growth Stocks With Major Incoming Catalysts ↗

June 27, 2023

Binary events slated for July could quickly send these biotech stocks through the roof.

Via The Motley Fool

BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference

June 20, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 13, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference

June 08, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 22, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 15, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 11, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.